Extended-release drugs to face extra scrutiny from FDA's new Office of Pharmaceutical Quality

"Modified release is a high-risk area, so we're going to put a lot of emphasis on it," said the deputy director of the FDA's new Office of Pharmaceutical Quality, Lawrence Yu during a press conference describing the new division. In addition, Janet Woodcock, who will head the new office, said there is a "huge scientific effort underway" at the FDA to find new ways of testing the effectiveness of modified or extended-release medications, such as recently approved Rytary for Parkinson's. Extended-release medications use drug delivery technologies to slow down the absorption of the active ingredient in the body. Recently there has been a rash of worries about the safety and efficacy of imported generics, including a withdrawal of Teva's ($TEVA) extended-release medication Wellbutrin for depression. Story | More on the Office of Pharmaceutical Quality

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…